Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Patterns of Care and Predictors of Survival in Adolescents and Young Adults with Hodgkin Lymphoma: A Population-Based Study

Justine M. Kahn, MD MS, Fran Maguire, PhD MPH, Qian Li, MS, Elysia Alvarez, MD MPH, Theresa H.M. Keegan, PhD MS

Blood (2019) 134 (Supplement_1): 2191.

https://doi.org/10.1182/blood-2019-129301

Published: 2019

Journal Articles

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

Phoebe Tsz Man Cheng, BSc,MD, Diego Villa, MD MPH, R. Petter Tonseth, MD, David W. Scott, MBChB, PhD, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Don Wilson, MD, Brian Skinnider, MD, Laurie H Sehn, MD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 2845.

https://doi.org/10.1182/blood-2019-122019

Published: 2019

Journal Articles

Metabolic Tumor Volume and Soluble Cytokines Levels in Newly Diagnosed Hodgkin Lymphoma: What It Brings into the Staging Precision?

VIT K Prochazka, MD, Lenka Henzlova, MD, Marie Lukasova, MD, Veronika Hanackova, MD, Eva Kriegova, Dr, assoc prof, Zuzana Mikulkova, Dr, Gabriela Gabcova, Dr, Jiri Minarik, MD PhD, Alice Sýkorová, MD PhD, Eva Krcalova, MD, Jiri Dolezal, MD assoc prof, Pavel Koranda, MD assoc prof, Tomas Papajik, MD prof

Blood (2018) 132 (Supplement 1): 2933.

https://doi.org/10.1182/blood-2018-99-115150

Published: 2018

Journal Articles

Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Karen E Effinger, MD MS, John Bergsagel, MD, Taylor Lawrence, Frank G Keller, MD, Rebecca Williamson Lewis, MPH, Lillian Meacham, MD, Ann Mertens, PhD, Sharon M. Castellino, MD MSc

Blood (2017) 130 (Supplement 1): 3466.

https://doi.org/10.1182/blood.V130.Suppl_1.3466.3466

Published: 2017

Journal Articles

Risk Adapted Treatment in Childhood Hodgkin's Lymphoma: Outcome and Changing Epidemiologic Features in 25 Years

Rejin Kebudi, MD Prof, Sema Bay Buyukkapu, MD, Omer Gorgun, MD, Fulya Yaman Agaoglu, MD, Bulent Zulfikar, MD, Inci Ayan, MD, Ayca Iribas, MD, Dizdar Yavuz, MD, Oner Dogan, MD, Emin Darendeliler, MD

Blood (2016) 128 (22): 4158.

https://doi.org/10.1182/blood.V128.22.4158.4158

Published: 2016

Journal Articles

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Tanya Mashiach, MSc, Elinor Barzilai, BSc, Abraham Korenberg, MD, Luiza Akria, MD, Tamar Tadmor, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Olga Kagna, MD, Rosa Ruchlemer, MD, Neta Goldschmidt, MD, Netanel A. Horowitz, MD, David Lavie, MD, Dina Ben-Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2016) 128 (22): 3001.

https://doi.org/10.1182/blood.V128.22.3001.3001

Published: 2016

Journal Articles

Tolerability and Efficacy of Treatments in Elderly Patients with Hodgkin Lymphoma: A Report from the Nebraska Lymphoma Study Group

Roberto A. Ferro, MD, Vijaya R. Bhatt, MD, Martin Bast, BS, Lynette Smith, MS, R. Gregory Bociek, MD, Matthew A. Lunning, DO, Philip J Bierman, MD, Julie M. Vose, MD, James O. Armitage, MD

Blood (2015) 126 (23): 1504.

https://doi.org/10.1182/blood.V126.23.1504.1504

Published: 2015

Journal Articles

Treating Hodgkin Lymphoma without Dacarbazine: A Lesson Learned from Thailand

Blood (2015) 126 (23): 5002.

https://doi.org/10.1182/blood.V126.23.5002.5002

Published: 2015

Journal Articles

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Michael J. Kelly, MD MPH, MS, Susan K Parsons, MDMRP, David C. Hodgson, MD, Joshua T Cohen, PhD, Jennifer M Yeh, MD PhD, Jeremy S. Abramson, MD, Debra L. Friedman, MD MS, Tara O Henderson, MDMPH, Peter W Johnson, MD, Stephen G Pauker, MD, John M. Raemaekers, MD PhD, Jane N. Winter, MD, Kara M. Kelly, MD, Ralph M. Meyer, MD, Sharon M Castellino, MD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 2635.

https://doi.org/10.1182/blood.V126.23.2635.2635

Published: 2015

Journal Articles

Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

Vit Prochazka, MD PhD ass. prof., Tereza Dyskova, Dr., Zuzana Prouzova, MD, Tomas Papajik, MD PhD prof., Jiri Minarik, MD PhD, Juraj Duras, MD, Jozef Michalka, MD, Alice Sykorova, MD PhD, Peter Mikula, MD, Ludek Raida, MD PhD, Eva Kriegova, Dr., PhD

Blood (2015) 126 (23): 4999.

https://doi.org/10.1182/blood.V126.23.4999.4999

Published: 2015

Journal Articles

Combined Modality Approach for Early Stage Unfavorable Hodgkin Lymphoma- Can We Avoid Radiation Therapy Based on Interim PET Imaging?

Van T Nguyen, MD, Judy P Tsai, MD, John P Greer, MD, David S Morgan, MD, Nishitha M Reddy, M.B.B.S.

Blood (2014) 124 (21): 5430.

https://doi.org/10.1182/blood.V124.21.5430.5430

Published: 2014

Journal Articles

Absolut Lymphocyte Count At Diagnosis Is Predictive Of Survival In Patients With Classical Hodgkin Lymphoma: A Retrospective Multicenter Brazilian Study

Guilherme Fleury Perini, MD, Egyla M Cavalcante, MD, Joao Garibaldi Rezende, Jr., MD, Davimar Miranda Borducchi, MD, Fernanda Cunha Vieira, MD, Danielle Leão Cordeiro Faria, MD, MS, Renato S Tavares, MD, Camila Almeida Amaral, Fabio S P Santos, MD, Nelson Hamerschlak, MD, PhD, Karin Zattar Cecyn, Eni Maria Souza, M.D, PhD, Adriana M. Damasco Penna, M.D, Otavio C.G. Baiocchi, MD, PhD

Blood (2013) 122 (21): 4236.

https://doi.org/10.1182/blood.V122.21.4236.4236

Published: 2013

Journal Articles

Systematic Review and Individual Patient Data Meta-Analysis Of Treatment-Related Risk Of Secondary Malignant Neoplasms After Hodgkin Lymphoma

Jeremy Franklin, PhD, Dennis A. Eichenauer, MD, Ingrid Becker, MSc, Andreas Engert, MD

Blood (2013) 122 (21): 1753.

https://doi.org/10.1182/blood.V122.21.1753.1753

Published: 2013

Journal Articles

CD68+ Tumor-Associated Macrophages Predict Unfavorable Treatment Outcomes in Classic Hodgkin's Lymphoma in Correlation with Early FDG-PET Assessment Results

Mohamed Touati, Manuela Delage-Corre, Jacques Monteil, Agnes Olivrie-Gamaury, Stephane Moreau, Liliane Remenieras, Marie-Pierre Gourin, Julie Abraham, Nataliya Dmytruk, Arnaud Jaccard, Dominique Bordessoule

Blood (2011) 118 (21): 1558.

https://doi.org/10.1182/blood.V118.21.1558.1558

Published: 2011

Journal Articles

BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group

Kara M. Kelly, Richard Sposto, Raymond Hutchinson, Vickie Massey, Kathleen McCarten, Sherrie Perkins, Mark Lones, Doojduen Villaluna, Michael Weiner

Blood (2011) 117 (9): 2596–2603.

https://doi.org/10.1182/blood-2010-05-285379

Published: 2011

Journal Articles

Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen

Lauren S. Maeda, MD, Richard T. Hoppe, MD, Saul A. Rosenberg, MD, Sandra J. Horning, MD, Ranjana H. Advani, MD

Blood (2010) 116 (21): 4828.

https://doi.org/10.1182/blood.V116.21.4828.4828

Published: 2010

Journal Articles

Immune Response Following Exposures to Topical Bovine Thrombin Does Not Impair Hemostasis

Craig Paterson, Glenn Pixton, Howard Proskin, Joseph Massaro, Ph.D., Mark Morasch, Jawed Fareed, PhD, Frederick Ofosu, PhD, Bruce Cronstein

Blood (2010) 116 (21): 1401.

https://doi.org/10.1182/blood.V116.21.1401.1401

Published: 2010

Journal Articles

Quality of Life of Long Term Survivors with Hodgkin's Lymphoma After High-Dose Chemotherapy with Autologous Stem Cell Transplantation and Conventional Chemotherapy.

Julia Brandt, Sascha Dietrich, Julia Meissner, Kai Neben, Anthony D. Ho, Mathias Witzens-Harig

Blood (2009) 114 (22): 2495.

https://doi.org/10.1182/blood.V114.22.2495.2495

Published: 2009

Journal Articles

Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.

Jacob Smeltzer, MD, Amanda F Cashen, MD, Qin Zhang, MS, Camille N. Abboud, MD, FACP, John F. DiPersio, MD, PhD, Keith Stockerl-Goldstein, MD, Geoffrey L. Uy, MD, Ravi Vij, MD, Peter Westervelt, MD, PhD, Nancy L Bartlett, MD, Todd A Fehniger, MD, PhD,

Blood (2009) 114 (22): 3417.

https://doi.org/10.1182/blood.V114.22.3417.3417

Published: 2009

Journal Articles

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

Filippo Russo, MD, Gaetano Corazzelli, MD, Secondo Lastoria, MD, Gianpaolo Marcacci, MD, Ferdinando Frigeri, MD, Gaetana Capobianco, Cristina Becchimanzi, MD, Manuela Arcamone, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 715.

https://doi.org/10.1182/blood.V114.22.715.715

Published: 2009

NARROW

Patterns of Care and Predictors of Survival in Adolescents and Young Adults with Hodgkin Lymphoma: A Population-Based Study

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

Metabolic Tumor Volume and Soluble Cytokines Levels in Newly Diagnosed Hodgkin Lymphoma: What It Brings into the Staging Precision?

Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Risk Adapted Treatment in Childhood Hodgkin's Lymphoma: Outcome and Changing Epidemiologic Features in 25 Years

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Tolerability and Efficacy of Treatments in Elderly Patients with Hodgkin Lymphoma: A Report from the Nebraska Lymphoma Study Group

Treating Hodgkin Lymphoma without Dacarbazine: A Lesson Learned from Thailand

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

Combined Modality Approach for Early Stage Unfavorable Hodgkin Lymphoma- Can We Avoid Radiation Therapy Based on Interim PET Imaging?

Absolut Lymphocyte Count At Diagnosis Is Predictive Of Survival In Patients With Classical Hodgkin Lymphoma: A Retrospective Multicenter Brazilian Study

Systematic Review and Individual Patient Data Meta-Analysis Of Treatment-Related Risk Of Secondary Malignant Neoplasms After Hodgkin Lymphoma

CD68+ Tumor-Associated Macrophages Predict Unfavorable Treatment Outcomes in Classic Hodgkin's Lymphoma in Correlation with Early FDG-PET Assessment Results

BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group

Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen

Immune Response Following Exposures to Topical Bovine Thrombin Does Not Impair Hemostasis

Quality of Life of Long Term Survivors with Hodgkin's Lymphoma After High-Dose Chemotherapy with Autologous Stem Cell Transplantation and Conventional Chemotherapy.

Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only